Abstract
Diffuse large B cell non-Hodgkin’s lymphomas (DLCL) form a heterogeneous group of tumors with diverse morphology, clinical features, treatment response and prognosis. The biological variables underlying this heterogeneity are unknown. In the present study, we explored the value of the lymphocyte homing receptor CD44, a putative determinant of lymphoma dissemination, in predicting prognosis in DLCL. Expression of the standard form of CD44 (CD44s) and of CD44 isoforms containing exon v6 (CD44v6) on tumor cells was assessed by immunohistochemistry in a cohort of 276 DLCL patients from a population based lymphoma registry. We observed that CD44s as well as CD44v6 expression correlated with tumor dissemination in patients with primary nodal DLCL. Importantly, in patients with localized nodal disease, CD44s was a strong prognosticator predicting tumor related death independent of the other parameters of the International Prognostic Index (IPI). Incorporation of CD44s in the IPI parameter ‘stage’, increased the prognostic value of this parameter in nodal DLCL. Our data identify CD44 as a biological prognosticator, which can be used to ‘fine-tune’ the IPI for nodal DLCL.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drillenburg, P., Wielenga, V., Kramer, M. et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 13, 1448–1455 (1999). https://doi.org/10.1038/sj.leu.2401490
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401490
- Springer Nature Limited
Keywords
This article is cited by
-
The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
Journal of Hematology & Oncology (2014)
-
CD44 in hematological neoplasias
Annals of Hematology (2011)
-
CD44H and CD44V6 Expression in Different Subtypes of Hodgkin Lymphoma
Modern Pathology (2000)